Imaging-Assisted Antisense Oligonucleotide Delivery for Tumor-Targeted Gene Therapy.

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antisense oligonucleotides (ASOs) are emerging as effective tools for targeting previously undruggable oncogenes.
• Several ASO candidates are currently in clinical trials for cancer therapy.
• Evaluating ASO efficacy and accuracy requires advanced assessment methods.

Purpose of the Study:

• To review the synergistic combination of molecular imaging techniques and delivery vehicles for enhanced antisense oligonucleotide (ASO) delivery.
• To explore strategies for improving ASO distribution and accumulation at tumor sites.
• To optimize therapeutic outcomes for antisense-based cancer treatments.

Main Methods:

• Systematic review of current literature on ASO delivery strategies.
• Exploration of molecular imaging techniques for qualitative and quantitative assessment of ASOs.
• Analysis of delivery vehicles designed to enhance oligonucleotide biodistribution and tumor accumulation.

Main Results:

• Molecular imaging provides critical insights into ASO pharmacokinetics and biodistribution.
• Synergistic approaches combining imaging and delivery vehicles can significantly enhance ASO tumor targeting.
• Optimized delivery improves ASO efficacy and therapeutic potential.

Conclusions:

• The integration of molecular imaging with advanced delivery systems is crucial for advancing antisense oligonucleotide therapeutics.
• This combined approach offers a powerful strategy for improving the efficacy and precision of ASO-based cancer treatments.
• Further research in this area holds significant promise for developing more effective oncogene-targeted therapies.